Endocrinol Metab.  2023 Feb;38(1):69-71. 10.3803/EnM.2023.104.

To Screen or Not to Screen?

• Park DJ

• KMID: 2539818
• DOI: http://doi.org/10.3803/EnM.2023.104

Reference

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212.

2. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med. 2014; 371:1765–7.

3. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017; 317:1338–48.

4. Christou N, Mathonnet M. Complications after total thyroidectomy. J Visc Surg. 2013; 150:249–56.

5. Moon S, Song YS, Jung KY, Lee EK, Park YJ. Lower thyroid cancer mortality in patients detected by screening: a meta-analysis. Endocrinol Metab (Seoul). 2023; 38:93–103.

6. Moon S, Lee EK, Choi H, Park SK, Park YJ. Survival comparison of incidentally found versus clinically detected thyroid cancers: an analysis of a nationwide cohort study. Endocrinol Metab (Seoul). 2023; 38:81–92.

7. Park JY, Choi W, Hong AR, Yoon JH, Kim HK, Kang HC. A comprehensive assessment of the harms of fine-needle aspiration biopsy for thyroid nodules: a systematic review. Endocrinol Metab (Seoul). 2023; 38:104–16.

8. Joo L, Lee MK, Lee JY, Ha EJ, Na DG. Diagnostic performance of ultrasound-based risk stratification systems for thyroid nodules: a systematic review and meta-analysis. Endocrinol Metab (Seoul). 2023; 38:117–28.

9. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, et al. Screening for thyroid cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2017; 317:1882–7.

10. Lee EK, Moon JH, Hwangbo Y, Ryu CH, Cho SW, Choi JY, et al. Progression of low-risk papillary thyroid microcarcinoma during active surveaillance: interim analysis of a multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma in Korea. Thyroid. 2022; 32:1328–36.

11. Olgers TJ, Ter Maaten JC. Point-of-care ultrasound curriculum for internal medicine residents: what do you desire?: a national survey. BMC Med Educ. 2020; 20:30.

12. Oteri V, Occhipinti F, Gribaudo G, Marastoni F, Chisari E. Integration of ultrasound in medical school: effects on physical examination skills of undergraduates. Med Sci Educ. 2020; 30:417–27.

13. American College of Radiology. Thyroid Imaging Reporting & Dat System (TI-RADSTM) [Internet]. Reston: ACR;2023. [cited 2023 Feb 9]. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/TI-RADS.

14. Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017; 143:1015–20.

15. Moon JH, Kim JH, Lee EK, Lee KE, Kong SH, Kim YK, et al. Study protocol of multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma (MAeSTro). Endocrinol Metab (Seoul). 2018; 33:278–86.

16. Jeon MJ, Kang YE, Moon JH, Lim DJ, Lee CY, Lee YS, et al. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in papillary thyroid microcarcinoma. Endocrinol Metab (Seoul). 2021; 36:359–64.

17. Ha EJ, Chung SR, Na DG, Ahn HS, Chung J, Lee JY, et al. 2021 Korean thyroid imaging reporting and data system and imaging-based management of thyroid nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol. 2021; 22:2094–123.

18. Kim K, Choi JY, Kim SJ, Lee EK, Lee YK, Ryu JS, et al. Active surveillance versus immediate surgery for low-risk papillary thyroid microcarcinoma patients in South Korea: a cost-minimization analysis from the MAeSTro study. Thyroid. 2022; 32:648–56.